Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
2
users have commented on this narrative
44
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
16
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
16
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Indraprastha Gas
AN
AnalystLowTarget
Consensus Narrative from 30 Analysts
Declining CNG Demand In Delhi Will Erode Long-Term Market Position
Key Takeaways Rapid adoption of electric vehicles and renewables is eroding core CNG demand, shrinking IGL's addressable market and threatening long-term growth prospects. Structural overreliance on Delhi-NCR and rising competition amplify revenue concentration risks, margin pressure, and potential for stranded asset exposure.
View narrative
₹155.00
FV
31.7% overvalued
intrinsic discount
2.52%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
Cegedim
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Legacy Challenges Will Test Healthcare Digitalization As Modest Opportunities Open
Key Takeaways Legacy IT reliance and underperformance in core divisions constrain growth, as newer digital competitors erode market share and hinder innovation. Limited international success and tightening regulatory demands restrict diversification, keeping growth dependent on mature home markets and pressuring profitability.
View narrative
€11.00
FV
3.2% undervalued
intrinsic discount
3.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
Berry
AN
AnalystLowTarget
Consensus Narrative from 5 Analysts
California Exposure Will Strain Operations While Utah Gains Mitigate Risks
Key Takeaways Heavy reliance on California operations increases exposure to strict regulations, political risks, and future revenue uncertainty. Global shift toward renewables and ESG scrutiny pose structural threats to long-term demand, margins, and financial flexibility.
View narrative
US$3.00
FV
5.3% undervalued
intrinsic discount
-0.30%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
Spin Master
AN
AnalystLowTarget
Consensus Narrative from 9 Analysts
Tariffs And Franchise Reliance Will Hinder Revenue Amid Digital Upside
Key Takeaways Heavy reliance on key franchises and licensed brands exposes Spin Master to significant revenue and gross margin volatility if any major IP underperforms. Higher input, operational, and promotional costs are pressuring margins, while global trade disruptions and demographic shifts challenge revenue growth and operational resilience.
View narrative
CA$23.90
FV
3.6% undervalued
intrinsic discount
1.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
Rigel Pharmaceuticals
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Regulatory Crackdowns And Pipeline Weakness Will Dominate Future Challenges
Key Takeaways Reliance on one-time revenue benefits, limited recurring income, and a narrow product portfolio creates significant risks for sustained earnings growth and long-term stability. Growing drug pricing pressures and shifting industry preferences away from small molecule therapies may reduce acquisition appeal, limit pricing power, and constrain future pipeline funding.
View narrative
US$23.00
FV
71.8% overvalued
intrinsic discount
-0.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
NATCO Pharma
AN
AnalystLowTarget
Consensus Narrative from 11 Analysts
Falling Revenues And Risky Diversifications Will Weaken Future Outlook
Key Takeaways Accelerating loss of key US revenue streams and mounting pricing pressures threaten profitability, with diversification efforts carrying execution risks and limited growth potential outside core markets. Rising R&D and compliance costs, without clear pipeline success, risk eroding returns and could further undermine long-term earnings amid escalating regulatory and supply chain challenges.
View narrative
₹748.00
FV
16.9% overvalued
intrinsic discount
-15.75%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
about 21 hours ago
author updated this narrative
inTEST
AN
AnalystLowTarget
Consensus Narrative from 2 Analysts
Soft Orders And Tensions Will Drag Revenue But Uncover Value
Key Takeaways Customer caution in key markets and ongoing geopolitical uncertainties are likely to constrain revenue growth and margin expansion despite new capacity and regional wins. Dependence on major accounts and shifting industry dynamics toward virtualized testing may cause earnings volatility and long-term pressure on physical product demand.
View narrative
US$8.00
FV
14.4% undervalued
intrinsic discount
3.50%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
accesso Technology Group
AN
AnalystLowTarget
Consensus Narrative from 3 Analysts
Growing Data Privacy Costs And Cybersecurity Demands Will Shrink Margins
Key Takeaways Rising regulatory demands, shifting consumer habits, and mounting competition threaten margins, long-term revenue growth, and market share for accesso's core offerings. Heavy reliance on theme parks and slow client migration to new platforms increase vulnerability to prolonged sales cycles and stalled recurring revenue growth.
View narrative
UK£4.36
FV
4.5% undervalued
intrinsic discount
1.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
ASTE
Aster DM Healthcare
AN
AnalystLowTarget
Consensus Narrative from 10 Analysts
Regulatory Pressures And Oversupply Will Undermine Indian Healthcare
Key Takeaways Regulatory pressures, wage inflation, and workforce shortages threaten profitability, operational efficiency, and the ability to sustain current margin levels amid ongoing expansion. Expansion risks, digital health disruption, and intensified competition may lead to diminished returns, reduced occupancy, and stagnant or declining revenue growth over time.
View narrative
₹449.63
FV
34.7% overvalued
intrinsic discount
18.33%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
about 21 hours ago
author updated this narrative
Value any company in seconds
Popular companies